Abstract
Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all malignant pancreatic neoplasms and constitutes the most frequent histopathologic entity among pancreatic neoplasms. Prognosis is mainly dependent on the stage of disease at diagnosis and overall outcomes are poor. KRAS-mutants are frequently observed in PDAC. There is, however, a percentage of PDAC cases with wild-type KRAS. ROS1 is a tyrosine kinase that has been recognized as a promising therapeutic target, when rearranged. Rearrangements have rarely been reported to be present in malignancies of the pancreato-biliary system, such as cholangiocarcinoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
